Novartis Gene Therapies

Session II, a visionary biotech entrepreneur, and the co-founder and CEO of Signifi Bio, a Dallas-based company on the cutting edge of personalized medicine.

With nearly two decades in the life sciences, R.A. has shaped the future of genetic medicine from leading gene therapy giants like AveXis and BridgeBio, to founding Taysha Gene Therapy, and taking it public in just six months, one of the fastest IPOs in biotech history.

We're gonna talk about that.

At Signifi Bio, he now leads a team backed by the Gates Foundation, Danaher Ventures, Eli Lilly Company, and others, advancing the mRNA protein therapeutics through groundbreaking delivery platforms like S-E-N-D, SEND, and IFOS.